Interestingly, we noted that αPD-1/4-1BB-treated mice bearing MHC-I-negative CT2A-TRP2-β2mKO tumors accumulated a greater number of TRP2-specific CD8+ T cells in the tumor than similarly treated mice bearing MHC-I-positive CT2A-TRP2 tumors (Fig. 2a and Extended Data Fig. 2a). The gene discussed is CD8A; the disease is neoplasm.